Research in context

Radical cure with primaquine or tafenoquine is currently only recommended in patients presenting with 
This multicentre trial assessed the safety and efficacy of high-dose short-course primaquine radical cure in patients presenting with uncomplicated 
Expanding the current indication for radical cure to include patients presenting with In areas co-endemic for Pooled analyses suggest that the greatest risk of Most endemic countries currently recommend a low-dose regimen of primaquine (total dose 3·5 mg/kg) for the radical cure of To better understand the risks and benefits of universal radical cure, we did a multicentre randomised, open-label trial to assess the safety of a high-dose short-course primaquine treatment (total dose 7 mg/kg over 7 days) in patients with 70% G6PD activity or greater and 